Floatz logo

Therapeutic Asset Ratings

245 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Iparomlimab
Neoadjuvant Immunotherapy
Tianjin Medical University Cancer Institute and HospitalP2B (60)
Pyrotinib
HER2 Positive
Tianjin Medical University Cancer Institute and HospitalP2B (60)
Selinexor
Extensive Stage Lung Small Cell Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (60)
Tucidinostat
HR Positive HER2 Negative Advanced Breast Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (60)
Tuvonralimab
Iparomlimab and Tuvonralimab Injection
Tianjin Medical University Cancer Institute and HospitalP2B (60)
CIS-DIAMMINEDICHLOROPLATINUM II
Colorectal Cancer
Tianjin Medical University Cancer Institute and HospitalP3B (59)
Fluzoparib
TNBC - Triple-Negative Breast Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (59)
Dc-Cik
Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and HospitalP2/3B (59)
Cyclophosphamide
Neoadjuvant Therapy
Tianjin Medical University Cancer Institute and HospitalP3B (58)
FLUOROURACILUM
Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and HospitalP3B (58)
Capecitabine
Liver Metastasis
Tianjin Medical University Cancer Institute and HospitalP2B (58)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2B (58)
Iparomlimab
Advanced Renal Cell Carcinoma
Tianjin Medical University Cancer Institute and HospitalP2B (58)
LENVATINIB
Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and HospitalP2B (58)
(+)-VINCRISTINE
Malignant Solid Tumor
Tianjin Medical University Cancer Institute and HospitalP2B (58)
Epirubicin
Neoadjuvant Therapy
Tianjin Medical University Cancer Institute and HospitalP3B (57)
Dabrafenib
Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Dabrafenib
BRAF V600 Colorectal Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Icotinib
EGFR L858R
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Icotinib
Tyrosine Kinase Inhibitor
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Irinotecan
EGFR L858R
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Irinotecan
Tyrosine Kinase Inhibitor
Tianjin Medical University Cancer Institute and HospitalP2B (57)
LENVATINIB
Gall Bladder Cancer
Tianjin Medical University Cancer Institute and HospitalP2B (57)
(+)-VINCRISTINE
EGFR L858R
Tianjin Medical University Cancer Institute and HospitalP2B (57)
(+)-VINCRISTINE
Tyrosine Kinase Inhibitor
Tianjin Medical University Cancer Institute and HospitalP2B (57)
Showing 51 to 75 of 245 assets
PreviousPage 3 of 10Next